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Abstract
Background: Of all patients with acute coronary syndrome with prolonged ST-segment
elevation (STEMI) 13–25% suffer from diabetes mellitus. Despite the introduction of fibrino-
lytic therapy, patients with STEMI and diabetes have worse prognosis than those without
diabetes. The introduction of primary angioplasty as the preferred method of treatment in this
group of patients has improved the prognosis somewhat. However, the problem has not been
totally solved and diabetic patients still show worse prognosis when compared to non-diabetics,
especially in long-term follow-up. The aim of our study was to compare short-term and long-term
outcomes in diabetic and non-diabetic patients treated with primary angioplasty for STEMI in
the Western Pomeranian Region of Poland between January and December 2003.
Methods: The medical files of patients treated for acute coronary syndromes in centres in the
Western Pomeranian Region of Poland were analysed. The inclusion criteria were hospitali-
sation between January 1st and December 31st of 2003 as a result of a first or subsequent
STEMI recognised according to European Cardiological Society guidelines. The study en-
rolled 329 patients including 60 diabetics (18.2%). The data obtained were categorised accord-
ing to the unified scheme including risk factors, coexisting diseases and a previous history of
myocardial infarction. The following parameters were analysed: complications of the acute
phase of myocardial infarction, 30-day mortality and one-year mortality.
Results: Significantly higher 30-day mortality was noted in diabetic patients who underwent
percutaneous revascularisation. Similar results were seen in one-year mortality, with values
almost four times as high as those for the non-diabetic group (p = 0.00023).
Conclusions: An analysis of the medical files of STEMI patients revealed a higher 30-day
mortality and a higher one-year mortality in those patients with coexisting diabetes. These
results cannot be attributed to delayed reperfusion therapy, TIMI flow in the related artery or
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adjuvant pharmacological therapy. The data obtained confirm the observation that diabetes is
an important factor in a poor prognosis in patients with acute coronary syndrome with
prolonged ST-segment elevation. (Folia Cardiol. 2006; 13: 486–493)
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complications of the acute phase of myocardial inf-
arction: ventricular fibrillation/flutter, third degree
heart block and cardiogenic shock, recognised on
the basis of clinical symptoms and a systemic systo-
lic blood pressure below 90 mm Hg or a sudden
drop in initial systolic blood pressure of 30 mm Hg
lasting at least 30 minutes without administration
of inotropic agents and intra-aortic balloon counter-
pulsation.
The data on percutaneous coronary interven-
tion (stent, platelet glycoprotein IIb/IIIa receptor
blocker and pre-procedure and post-procedure
TIMI) were analysed. Hyperlipidaemia was evalu-
ated using widely applied criteria: total cholesterol
level ≥ 200 mg/dl, LDL-cholesterol level ≥ 130 mg/dl,
HDL-cholesterol level £ 40 mg/dl, triglyceride level
≥ 200 mg/dl. The use of oral hypoglycaemic agents
or insulin on admission day was recognised as evi-
dence of the presence of diabetes mellitus (Table 1).
Evaluation of late mortality was performed on
the basis of a questionnaire sent to all patients.
These data were recorded between June 2004 and
December 2004. The cases without response were
verified on the basis of telephone contact and data from
the Regional Registry, Regional Office, Szczecin.
Statistical analysis
The patient’s age was the only continuous var-
iable (data are shown as means and minimal and
maximal values). Normal distribution of the contin-
uous variables was tested with the Shapiro-Wilk
test and the homogeneity of variance in the groups
compared was tested with the Snedecor and Brown-
Forsythe tests. Since the majority of variables were
not normally distributed, non-parametric methods,
namely the Kruskal-Wallis and Mann-Whitney U
tests, were applied in the comparisons of means so
that uniform calculations could be performed.
Qualitative variables were tested with Pear-
son’s c2 test of independence. Fisher’s exact test
was applied for the 2 × 2 contingency tables at ex-
pected frequencies £ 40, and Yates’ correction was
applied for the 2 × 2 contingency tables at expect-
ed frequencies £ 10.
Owing to the retrospective nature of the study
and the paucity of documentation we failed to
Introduction
Diabetic patients make up 13–25% of patients
suffering from ST-segment elevation myocardial in-
farction (STEMI) [1–7]. Despite the introduction of
fibrinolytic therapy, the outcomes in STEMI patients
with diabetes remain unsatisfactory [8–11]. The in-
troduction of primary coronary angioplasty as the
preferred method of treatment in this group of pa-
tients has improved the prognosis. Diabetic patients
still have a worse prognosis when compared to non-
diabetics, especially in long-term follow-up [12, 13].
The introduction of platelet glycoprotein IIb/IIIa re-
ceptor blockers and stents has reduced mortality to
the rates seen in non-diabetic patients [14].
The aim of our study was to compare the short-
-term and long-term outcomes in diabetic and non-
-diabetic patients subjected to percutaneous inter-
vention in the Western Pomeranian Region of Po-
land between January and December 2003.
Methods
The medical files of patients from centres treat-
ing acute coronary syndromes in the Western Po-
meranian Region were subjected to retrospective
analysis. The centres providing invasive procedures
in the treatment of acute myocardial infarction in-
cluded two from Szczecin and one from Koszalin.
The inclusion criterion was hospitalisation as a re-
sult of first or consecutive acute myocardial infarc-
tion with STEMI in accordance with the criteria ac-
cepted by the European Cardiological Society [15].
The study group enrolled all consecutive pa-
tients with STEMI hospitalised in the centres re-
ferred to above and scheduled for primary coronary
angioplasty between January 1st 2003 and Decem-
ber 31st, 2003. The data obtained from the medical
files were recorded uniformly in a protocol. Includ-
ed were risk factors such as smoking, high total
cholesterol and LDL cholesterol levels, coexisting
disease (arterial hypertension, gouty diathesis, atri-
al fibrillation, a previous history of stroke/TIA) and
a positive history of previous myocardial infarctions.
The duration of chest pain from onset to admis-
sion to hospital was analysed as were the following
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collect complete data for all diabetic patients. Thus
we intentionally abandoned multivariate analysis.
For all calculations the accepted level of sig-
nificance was p = 0.05.
Early outcomes
Between January 1st 2003 and December 31st
2003 primary coronary angioplasty was performed
in 329 patients, including 60 diabetic patients
(18.2%). The mean patient age was 60 years, 62.6
years for the diabetic group and 57.46 years for the
non-diabetic group (p = 0.0022).
A statistically significantly higher incidence of
coexisting arterial hypertension (p = 0.00017) and
previous myocardial infarctions (p = 0.00213) were
found in the diabetic group. Significantly lower to-
tal cholesterol (p = 0.01828) and LDL-cholesterol
(p = 0.02052) levels and significantly higher
HDL-cholesterol (p = 0.01541) levels were found
in the diabetic group.
Analysis of the time between the onset of my-
ocardial infarction symptoms and initiation of the
revascularisation procedure revealed that the ma-
jority of patients had received definite care within
6 hours of the onset (75%). No significant correla-
tion was found between the groups studied in the
categorised time from the onset of chest pain to
coronary intervention. Detailed data on the time
from the onset of myocardial infarction symptoms
to coronary intervention are shown in Table 2.
In the diabetic patients the most frequently
affected vessels turned out to be the right coronary
artery and the left anterior descending coronary
artery. The difference was non-significant. The
detailed distribution is shown in Table 3.
In both groups of patients a high rate of stent
implantation was noted, 83.3% in the diabetic group
and 79.9% in the non-diabetic group (NS). The use
of platelet glycoprotein IIb/IIIa receptor blockers
was at unacceptably low rates, 15.0% and 17.4%
Table 2. Time from onset of symptoms to admission to hospital.
Diabetes mellitus group (n = 58*) Non-diabetes mellitus group (n = 237) p
Time to 6 h 39 (67.24%) 182 (76.79%) NS**
Time > 6 h 19 (32.76%) 55 (23.21%) NS**
Time > 12 h 9 (15.52%) 28 (11.81%) NS**
*Information for these patients only; **Pearson’s c 2 test
Table 1. Baseline characteristics of patients with STEMI.
Parameters Whole group Diabetes mellitus Non-diabetes mellitus p
(n = 329)  group (n = 60)  group (n = 269)
Age of patients: 60 (32–85) 62.6 (43–85) 57.4 (32–83) 0.002222**
middle (min and max)
Hypertension 204 (61.3%) 48 (84.2%) 156 (56.5%) 0.00017
(> 140/90mm Hg)
Smoking 190 (59.4%) 17 (38.6%) 173 (62.7%) 0.00436
Stroke/TIA 6 (2.1%) 1 (2.7%) 5 (2.0%) NS
Gout 2 (0.7%) 0 (0%) 2 (0.7%) NS
Renal insufficiency 2 (0.7%) 1 (2.7%) 1 (0.4%) NS
Former infarct 47 (16%) 14 (33.3%) 33 (13.2%) 0.00213
High level 113 from 238* 9 from 33 104 from 205* 0.02052
LDL-cholesterol (47.5%) (27.3%) (50.7%)
Low level 38 from 238* 10 from 33 28 from 205* 0.01541
HDL-cholesterol (13.9%) (30.3%) (13.7%)
High level total 145 from 255* 12 from 33 133 from 222* 0.01828
cholesterol (56.9%) (36.4%) (59.9%)
Left ventricular 47.4% 45.6% 47.6% NS
ejection fraction
*Information for these patients only; **Mann-Whitney U-test
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respectively. The difference was non-significant
(Table 4).
The angiographic analysis did not reveal any
significant differences between the groups in the
TIMI flow grades achieved within the infarct-relat-
ed artery. These data are shown in Table 5.
Statistically insignificantly lower left ventricle
ejection fraction values were found in the diabetic
group.
Pharmacotherapy
When analysing in-hospital therapy we found that
large numbers of patients received adjunctive treat-
ment, including beta-blockers, hypolipidaemic agents
and ACE inhibitors. No significant differences in drug
administration were found between the groups stud-
ied. A similar pre-surgery protocol of percutaneous
revascularisation was followed in both groups. The
majority of patients received 300 mg acetylsalicylic
acid, tienopiridine and intravenous unfractionated
heparin administered directly before the surgery.
Similar results were obtained in the long-term
analysis of pharmacotherapy. Again it was found that
a large number of patients were receiving beta-
-blockers and hypolipidaemic agents. However, ACE
inhibitors were statistically significantly more fre-
quently administered in the diabetic group. The
details are shown in Tables 6 and 7.
Table 3. Infarct-related artery.
Diabetes mellitus group (n = 60) Non-diabetes mellitus group (n = 269) p
Left anterior descending 26 (43.3%) 127 (46.9%) NS*
Right coronary artery 7 (11.7%) 39 (14.7%) NS*
Left circumflex artery 27 (45%) 103 (38.5%) NS*
*Pearson’s c2 test
Table 4. Use of stents and IIb/IIIa blockers.
Diabetes mellitus group (n = 60) Non-diabetes mellitus group (n = 269) p
Stent 50 (83.3%) 215 (79.9%) NS
IIb/IIIa blockers 9 (15%) 47 (17.4%) NS
Table 5. TIMI flow after percutaneous transluminal intervention.
Diabetes mellitus group (n = 60) Non-diabetes mellitus group (n = 269) p
2 and 3 TIMI flow 89.36% 94.97% NS
Table 6. In-hospital pharmacological treatment.
Diabetes mellitus group Non-diabetes mellitus group
Acetylosalicylic acid 32 (94.1%) 220 (93.2%)
Beta-blocker 31 (91.2%) 202 (85.6%)
Angiotensin-converting enzyme inhibitors 26 (76.5%) 167 (70.8%)
Calcium-channels blocker 1 (2.9%) 11 (4.7%)
Hypolipidaemic agents 30 (88.2%) 205 (87.2%)
Diuretics 4 (11.8%) 19 (8.1%)
Nitrates 9 (26.5%) 85 (36%)
Tienopirydynes 31 (91.2%) 209 (87.1%)
p = NS
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In-hospital complications
No significant differences were found be-
tween the groups studied in the rates of severe
complications in the acute phase of myocardial inf-
arction (ventricular fibrillation and flutter and third
degree heart block). However, a significant differ-
ence was found with respect to cardiogenic shock,
which occurred more frequently in the diabetic pa-
tients (13.2%) than in the non-diabetic group (5.3%)
(p = 0.0332). Details are shown in Table 8.
30-day and one-year mortality
A significantly higher 30-day mortality was
noted in diabetic patients subjected to a percutane-
ous revascularisation procedure. Similarly, one-
year mortality was almost four times higher than
in the non-diabetic group (p = 0.00023). The de-
tails are shown in Table 9.
The analysis revealed that 30-day mortality
among the patients as a whole was significantly af-
fected by previous myocardial infarction. Moreover,
one-year mortality was additionally influenced by
previous stroke. In this group non-smokers showed
a higher probability of 30-day and one-year mortal-
ity. However, in the diabetic group no correlation
between 30-day mortality and other risk factors was
found. The only correlation found was between pre-
vious myocardial infarction and one-year mortality
(Tables 10 and 11).
Discussion
In the population with acute STEMI from the
Western Pomeranian Region of Poland the preva-
lence of diabetic patients was 18.2%, a result com-
parable to registries elsewhere in Europe and
worldwide [1, 3–5, 16].
The mean age of patients treated with coronary
interventions was 60 years, a result comparable to
the age of patients from the majority of European
registries and the Silesian Myocardial Infarction
Registry [3–7]. STEMI patients with coexisting di-
abetes were significantly older and more frequent-
ly had a history of myocardial infarction and arteri-
al hypertension. Similar data have been reported by
other researchers [16–19].
Table 9. 30-day and one-year mortality.
Diabetes mellitus group Non-diabetes mellitus group p
30-day mortality 7 (11.5%) 11 (4%) 0.01855
One-year mortality 13 (22.8%) 17 (6.3%) 0.00023
Table 7. Pharmacological treatment in patients with STEMI during follow-up.
Diabetes mellitus group Non-diabetes mellitus group p
Acetylosalicylic acid 20 (90.9%) 132 (91.7%) NS
Beta-blocker 20 (90.9%) 119 (83.8%) NS
Angiotensin-converting 20 (90.9%) 93 (66.9%) 0.0471
enzyme inhibitors
Calcium-channels blocker 1 (4.55%) 8 (5.7%) NS
Hypolipidaemic agents 20 (90.9%) 127 (89.4%) NS
Nitrates 8 (36.4%) 50 (35.7%) NS
Table 8. Infarct complications.
All group Diabetes mellitus Non-diabetes p
group  mellitus group
Ventricular fibrillation/flutter 17 2 (4%) 15 (5.6%) NS
and ventricular tachycardia
Complete block 4 0 (0%) 4 (1.5%) NS
Cardiogenic shock 21 7 (13.2%) 14 (5.3%) 0.0332
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Diabetic neuropathy is a very important factor
influencing the clinical course of myocardial infarc-
tion in patients with diabetes mellitus. Damage to
the autonomous nervous system results in persist-
ent tachycardia and a painless or atypical course of
acute coronary syndromes is frequently observed.
Moreover, hypoglycaemic agents influence the
electrocardiogram and may result in a delay in the
introduction of reperfusion therapy among diabetic
patients [20]. A similar delay in the application of
percutaneous reperfusion therapy was observed in
diabetic patients with cardiogenic shock [21].
In our analysis the time that elapsed from the
onset of coronary symptoms to the initiation of in-
vasive management was comparable in both groups
and we did not observe any additional delay in the
initiation of therapy resulting from coexisting dia-
betes mellitus. Similar observations have been not-
ed by authors reporting from the Cracow Region of
Poland [17].
The effectiveness of coronary angioplasty
based on TIMI flow was similar in diabetic and non-
diabetic patients, an observation in agreement with
results reported by other authors [22]. However,
it should be underlined that previous analyses had
already indicated that TIMI epicardial flow grade
was not the only indicator of normal myocardial tis-
sue perfusion [23]. The nature of our study prevent-
ed us from performing a detailed analysis of this
problem based on, for example, the myocardial
blush grade.
A comparison of adjunctive pharmacotherapy
revealed no differences between the groups of pa-
tients studied in the administration of each drug
group. This observation differs from those report-
ed in the literature. Other authors have reported
lower rates of administration of beta-blockers and
acetylsalicylic acid in diabetic patients [5, 6].
Platelets and thrombogenesis contribute sig-
nificantly to the pathophysiology of cardiovascular
diseases. The increased risk of vascular incidents in
diabetes results from platelet hyperactivity, fibrino-
lytic disequilibrium, endothelial dysfunction and im-
paired blood flow [24]. The recently underlined poor
platelet response to acetylsalicylic acid in diabetic
patients should result in administration of platelet
glycoprotein IIb/IIIa receptor blockers [25].
Recent age-adjusted studies have revealed
decreased mortality in patients with cardiovascu-
lar system diseases. This is not, however, noticea-
ble among diabetic patients, although widely applied
stents and platelet glycoprotein IIb/IIIa receptor
blockers have resulted in significant progress in
mortality limitation in this group of patients [12, 26].
Table 10. Risk factors and mortality in whole group.
30-days follow-up Year follow-up
Current Absent p Current Absent p
Hypertension 6.51 (17/261) 4.65 (6/129) 0.61281 10.97 (26/237) 8.59 (11/128) 0.59183
Stroke 16.67 (1/6) 4.64 (13/80) 0.69322 33.33 (2/6) 7.35  (20/272) 0.01971
Smoking 1.58 (3/190) 8.46 (11/130) 0.00741 2.69 (5/186) 13.49 (17/126) 0.00060
Atrial fibrillation 0 (0/11) 5.09 (14/275) 0.95629 18.18 (2/12) 7.49 (20/262) 0.47311
Gout 0 (0/2) 4.93 (14/84) 0.18604 0.00 (0/2) 7.97 (22/276) 0.36900
Former infarct 17.19 (11/64) 3.25 (8/246) 0.00012 26.23 (16/61) 5.04 (12/238) 0.00001
In brackets — number of deaths/number of patients with or without a particular risk factor.
Table 11. Risk factors and mortality in subgroup with diabetes mellitus.
30-days follow-up Year follow-up
Current Absent p Current Absent p
Hypertension 14.58 (7/48) 0 (0/9) 0.50295 27.27 (12/44) 11.11 (1/9) 0.54743
Stroke 0 (0/1) 8.33 (3/36) 0.91892 100.00 (1/1) 12.12 (4/33) 0.14706
Smoking 0 (0/17) 11.11 (3/36) 0.41818 0 (0/16) 20.00 (5/25) 0.15565
Atrial fibrillation 0 (0/2) 8.57 (3/35) 0.84234 50.00 (1/2) 12.50 (4/32) 0.27629
Former infarct 21.43 (3/14) 7.14 (2/28) 0.39963 42.86 (6/14) 8.00 (2/25) 0.01609
In brackets — number of deaths/number of patients with or without a particular risk factor.
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In our research we noted that stenting proce-
dures were performed at a significant rate in both
groups of patients (diabetic patients: 83.3%, non-
-diabetic patients: 79.9%, the difference being non-
-significant).
The National Health Fund in Western Pomer-
ania failed to reimburse the therapeutic pro-
grammes for interventional cardiology; thus the un-
satisfactory use of platelet glycoprotein IIb/IIIa re-
ceptor blockers in the STEMI patients came as no
surprise (15.0% and 17.4%, respectively, the differ-
ence being non-significant). This observation was
a likely cause of higher in-hospital mortality rates
in diabetic patients.
Analysis of in-hospital complications revealed
a significant difference between the groups studied
in the occurrence of cardiogenic shock: the diabet-
ic patients showed higher rates of cardiogenic shock
than non-diabetic patients (13.2% vs. 5.3%; p =
= 0.0332). Similar observations have been reported
by other authors [19, 27].
The adverse influence of diabetes mellitus on
short-term and long-term survival in patients with
acute myocardial infarction was confirmed by the
results of our study. The 30-day mortality in diabet-
ic patients subjected to percutaneous revascularisa-
tion was significantly higher at 11.5% as compared
with 4% in the non-diabetic group of patients. More-
over, one-year mortality was almost four times as
high in the diabetic group as in the non-diabetic pa-
tients (p = 0.00023). This is consistent with the re-
sults achieved by other authors [5, 6, 16, 19, 28–32].
Limitations of the study
The medical files from the three centres in
Western Pomerania providing invasive treatment
for acute myocardial infarction were the source of
data used in the present study. Shortcomings in the
standards of documentation and latitude in the in-
terpretation of clinical facts were the likely causes
of data being inconsistent or missing. Analysis of
long-term outcomes was based on questionnaires
received from the patients and these files were also
inconsistent, which might have influenced the con-
clusions.
Conclusions
The present analysis, performed in a popula-
tion with ST-segment elevation myocardial infarc-
tion revealed higher 30-day mortality and one-year
mortality in diabetic patients. These results cannot
be attributed to delayed reperfusion therapy, TIMI
flow in the related artery or adjuvant pharmacolo-
gical therapy. The data obtained confirm the obser-
vation that diabetes is an important factor of poor
prognosis in patients with acute coronary syndrome
with prolonged ST-segment elevation.
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